Which of progestogens used in combined oral contraceptives are associated with a higher risk of thrombosis? Generally speaking, modern combined hormonal contraceptives are associated with only a minor increase in the risk of thrombosis. This risk depends predominantly on progestogen included in the drug, and, to a smaller degree, on the dose of estrogen (at least in the range of 20 to 35 µg of ethinylestradiol). Levonorgestrel seems to be the safest progestogen in the context of venous thromboembolism (VTE). It is used as a reference molecule in most studies assessing the effect of combined oral contraceptives on the risk of VTE. Norgestimate is another progestogen that is associated with a relatively small increase in the risk of VTE. A relatively higher increase in the risk of VTE was observed for combined oral contraceptives containing such progestogens as gestodene, desogestrel, and drospirenone.
Which hormonal contraceptives, if any, can be used in young female smokers? Smoking is not a contraindication to combined oral contraceptives in women younger than 35 years of age. However, simultaneous smoking and using the combined oral contraceptives may increase the risk of VTE, especially in women of late reproductive age. In young female smokers, the use of low -dose combined oral contraceptives, combined oral contraceptives containing natural estrogens (estradiol or estradiol valerate), or an intrauterine device is preferable. 
